These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27790956)

  • 1. Biological voyage of solid lipid nanoparticles: a proficient carrier in nanomedicine.
    Ali H; Singh SK
    Ther Deliv; 2016 Oct; 7(10):691-709. PubMed ID: 27790956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption, pharmacokinetics and disposition properties of solid lipid nanoparticles (SLNs).
    Wang J; Chen J; Ye N; Luo Z; Lai W; Cai X; Lin Y
    Curr Drug Metab; 2012 May; 13(4):447-56. PubMed ID: 22443539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art.
    Weber S; Zimmer A; Pardeike J
    Eur J Pharm Biopharm; 2014 Jan; 86(1):7-22. PubMed ID: 24007657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle.
    Harde H; Das M; Jain S
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1407-24. PubMed ID: 21831007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cationic ligand appended nanoconstructs: a prospective strategy for brain targeting.
    Agarwal A; Agrawal H; Tiwari S; Jain S; Agrawal GP
    Int J Pharm; 2011 Dec; 421(1):189-201. PubMed ID: 21986113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations.
    Ramalingam P; Ko YT
    Pharm Res; 2015 Feb; 32(2):389-402. PubMed ID: 25082210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution of lipid nanoparticles: a comparative study of pulmonary versus intravenous administration in rats.
    Videira MA; Santos AC; Botelho MF
    Curr Radiopharm; 2012 Apr; 5(2):158-65. PubMed ID: 22280113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transport of stearic acid-based solid lipid nanoparticles (SLNs) into human epithelial cells.
    Shah RM; Rajasekaran D; Ludford-Menting M; Eldridge DS; Palombo EA; Harding IH
    Colloids Surf B Biointerfaces; 2016 Apr; 140():204-212. PubMed ID: 26764103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption, disposition and pharmacokinetics of solid lipid nanoparticles.
    Qi J; Lu Y; Wu W
    Curr Drug Metab; 2012 May; 13(4):418-28. PubMed ID: 22443536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo fate of lipid-based nanoparticles.
    Qi J; Zhuang J; Lu Y; Dong X; Zhao W; Wu W
    Drug Discov Today; 2017 Jan; 22(1):166-172. PubMed ID: 27713035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation, characterization, and in vitro/vivo studies of aclacinomycin A-loaded solid lipid nanoparticles.
    Jia Y; Ji J; Wang F; Shi L; Yu J; Wang D
    Drug Deliv; 2016 May; 23(4):1317-25. PubMed ID: 25371296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoemulsions (NEs), liposomes (LPs) and solid lipid nanoparticles (SLNs) for retinyl palmitate: effect on skin permeation.
    Clares B; Calpena AC; Parra A; Abrego G; Alvarado H; Fangueiro JF; Souto EB
    Int J Pharm; 2014 Oct; 473(1-2):591-8. PubMed ID: 25102113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethyl oleate-containing nanostructured lipid carriers improve oral bioavailability of trans-ferulic acid ascompared with conventional solid lipid nanoparticles.
    Zhang Y; Li Z; Zhang K; Yang G; Wang Z; Zhao J; Hu R; Feng N
    Int J Pharm; 2016 Sep; 511(1):57-64. PubMed ID: 27374194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid nanovehicles with adjustable surface properties for overcoming multiple barriers simultaneously in oral administration.
    Wu L; Liu M; Shan W; Cui Y; Zhang Z; Huang Y
    Int J Pharm; 2017 Mar; 520(1-2):216-227. PubMed ID: 28185960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained release of piroxicam from solid lipid nanoparticle as an effective anti-inflammatory therapeutics in vivo.
    Peng LH; Wei W; Shan YH; Chong YS; Yu L; Gao JQ
    Drug Dev Ind Pharm; 2017 Jan; 43(1):55-66. PubMed ID: 27498809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of solid lipid nanoparticles for sustained drug release.
    Attama AA; Umeyor CE
    Ther Deliv; 2015; 6(6):669-84. PubMed ID: 26149784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological assessment of follicular delivery of flutamide by solid lipid nanoparticles: potential tool for the treatment of androgenic alopecia.
    Hamishehkar H; Ghanbarzadeh S; Sepehran S; Javadzadeh Y; Adib ZM; Kouhsoltani M
    Drug Dev Ind Pharm; 2016; 42(6):846-53. PubMed ID: 26154267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted SLNs for management of HIV-1 associated dementia.
    Rai A; Jain A; Jain A; Jain A; Pandey V; Chashoo G; Soni V; Sharma PR
    Drug Dev Ind Pharm; 2015; 41(8):1321-7. PubMed ID: 25113430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
    Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
    Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicine: sizing up targets with nanoparticles.
    Minchin R
    Nat Nanotechnol; 2008 Jan; 3(1):12-3. PubMed ID: 18654442
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.